2023 Nobel Prize in Physiology or Medicine

Award From Wikipedia, the free encyclopedia

2023 Nobel Prize in Physiology or Medicine

The 2023 Nobel Prize in Physiology or Medicine was awarded to Katalin Karikó (born 1955) and Drew Weissman (born 1959) "for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19".[2][3]

Quick Facts The 2023 Nobel Prize in Physiology or Medicine, Date ...
The 2023 Nobel Prize in Physiology or Medicine
ThumbThumb
Karikó (left) and Weissman (right) "for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19"
Date2 October 2023 (2023-10-02)
LocationStockholm
CountrySweden
Presented byNobel Assembly at Karolinska Institutet
Hosted byThomas Perlmann
Reward(s)11 million SEK (2023)[1]
First award1901
Website2023 Nobel Prize in Physiology or Medicine
 2022 · Nobel Prize in Physiology or Medicine · 2024 
Close

Laureates

Katalin Karikó

Katalin Karikó was born on January 17, 1955, in Szolnok, Hungary.[4] From the University of Szeged, she received a Ph.D. in biochemistry in 1982.[5] From 2013 to 2022, she was associated with BioNTech RNA Pharmaceuticals, first as a vice president and promoted to senior vice president in 2019. This company, a division of BioNTech, commercialized mRNA vaccines at a global scale.

Drew Weissman

Drew Weissman was born on September 7, 1959, in Lexington, Massachusetts[6] and received a Ph.D. in 1987 at Boston University.[7] He started studying RNA at the University of Pennsylvania in 1997,[8] where he met Karikó.[9]

Key publications

The following publications were the fundamental researches that motivated the Nobel Assembly at Karolinska Institutet to award the 2023 Prize to Karikó and Weissman:[10]

  • Karikó, K., Buckstein, M., Ni, H. and Weissman, D. Suppression of RNA Recognition by Toll-like Receptors: The impact of nucleoside modification and the evolutionary origin of RNA. Immunity 23, 165–175 (2005).
  • Karikó, K., Muramatsu, H., Welsh, F.A., Ludwig, J., Kato, H., Akira, S. and Weissman, D. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 16, 1833–1840 (2008).
  • Anderson, B.R., Muramatsu, H., Nallagatla, S.R., Bevilacqua, P.C., Sansing, L.H., Weissman, D. and Karikó, K. Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. Nucleic Acids Res. 38, 5884–5892 (2010).

References

Wikiwand - on

Seamless Wikipedia browsing. On steroids.